Anti-class II -DR humanized monoclonal antibody, IMMU-114, blocks allogeneic immune response

Abstract

BackgroundThe effect of a humanized anti–human leukocyte antigen–DR monoclonal antibody, IMMU-114, on the allogeneic immune response was investigated in vitro. MethodsResponder peripheral blood mononuclear cells were cocultured with inactivated self or allogeneic stimulator peripheral blood mononuclear cells in the presence of control antibody or IMMU-114. Thymidine incorporation rates were then measured. Phenotypic changes in peripheral blood mononuclear cells and the intracellular Th1-type cytokines interleukin-2, interferon-γ, and tumor necrosis factor–α were analyzed using flow cytometry. The concentrations of interleukin-2, interferon-γ, and tumor necrosis factor–α in the mixed lymphocyte reaction culture medium were measured. ResultsThymidine incorporation rates at a 1:1 responder/stimulator ratio of allogeneic, allogeneic + IMMU-114, self, and self + IMMU-114 were 22,080.7 ± 602.4, 2,254.5 ± 118.1, 1,284.0 ± 227.8, and 494.5 ± 27.5 cpm, respectively (P = .038). IMMU-114 decreased the frequencies of human leukocyte antigen–DR–expressing CD16+56+ NK cells, CD19+ B cells, and CD3+25+ activated T cells. ConclusionIntracellular cytokine assay and measurement of Th1-type cytokines in the mixed lymphocyte reaction culture medium revealed that IMMU-114 significantly decreased the titers of interleukin-2, interferon-γ, and tumor necrosis factor–α. IMMU-114 significantly suppresses the allogeneic immune response in vitro, partly through inhibition of the Th1 response.